US Senators introduce major Rx drug pricing reform to lower costs for Americans

24 July 2019

The leading members of the USA’s Senate Finance Committee on Tuesday unveiled a long-awaited bipartisan bill to ease drug prices by increasing drugmaker rebates and demanding more scrutiny of price hikes, which is projected to save the federal government $85 billion on drug spending over the next decade.

Senate Finance Committee Chairman Chuck Grassley (Republican, Iowa) and Ranking Member Ron Wyden (Democrat, Oregon) introduced a chairman’s mark, the Prescription Drug Pricing Reduction Act (PDPRA) of 2019, to lower the price of prescription drugs for Americans.

The committee also announced a markup for the legislation will be held on Thursday, July 25 at 9:30 am ET. Text of the chairman’s mark can be found HERE.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK